-+ 0.00%
-+ 0.00%
-+ 0.00%

Valion Bio briefs Department of War, BARDA officials on Entolimod for radiation syndrome

PUBT·05/19/2026 20:39:23
Listen to the news
Valion Bio briefs Department of War, BARDA officials on Entolimod for radiation syndrome
  • Valion Bio briefed senior U.S. Department of War officials alongside BARDA in a joint engagement on May 14, 2026, focused on Entolimod for acute radiation syndrome.
  • Valion Bio highlighted interest in a field-deployable oral formulation as it advances Entolimod toward a Biologics License Application under the FDA’s Animal Rule, with about $35.6 million in prior U.S. government funding for the program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605191638PR_NEWS_USPR_____CL63517) on May 19, 2026, and is solely responsible for the information contained therein.